Dashboard
Manage Tickers

ENTX Entera Bio Ltd.

Nasdaq enterabio.com


$ 2.33 $ -0.06 (-2.49 %)    

Friday, 17-Oct-2025 15:55:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.35
$ 2.42
$ 2.32 x 86
$ 2.45 x 400
$ 2.25 - $ 2.43
$ 1.50 - $ 2.95
61,831
na
110.07M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-28-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-08-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

entera-bio-announces-it-will-present-new-phase-2-clinical-data-for-eb613-at-the-north-american-menopause-society-2025-annual-meeting-october-2125-2025-in-orlando-florida
Entera Bio Announces It Will Present New P...
10/16/2025 12:47:45

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced t...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
10/15/2025 12:09:47

entera-bio-presents-preclinical-data-for-opk-8801003-oral-glp-2-tablet-with-longer-half-life-aiming-to-replace-daily-injections-for-short-bowel-syndrome-patients
Entera Bio Presents Preclinical Data For O...
09/15/2025 13:05:56

Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Ga...

entera-bio-to-present-eb613-phase-2-data-at-asbmr-2025-oral-anabolic-tablet-advances-toward-phase-3
Entera Bio To Present EB613 Phase 2 Data A...
09/08/2025 12:33:16

EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Ph...

entera-bio-q2-eps-006-misses-121-estimate
Entera Bio Q2 EPS $(0.06) Misses $1.21 Est...
08/08/2025 20:10:04

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $1.21 by...

entera-bio-receives-fda-agreement-to-support-eb613-nda-filing-with-single-24-month-global-phase-3-study-in-postmenopausal-osteoporosis-using-total-hip-bmd-as-primary-endpoint-and-vertebral-fracture-incidence-as-key-secondary
Entera Bio Receives FDA Agreement To Suppo...
07/28/2025 11:32:25

Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today ...

Core News & Articles
OPKO Health And Entera Bio To Present Abst...
07/08/2025 12:09:42

entera-bio-selected-to-present-data-for-eb613-effects-on-trabecular-and-cortical-bone-in-post-menopausal-women-with-osteoporosis-at-asbmr-2025-annual-meeting
Entera Bio Selected To Present Data For EB...
06/26/2025 12:10:49

Core News & Articles
OPKO Health And Entera Bio Say New Pharmac...
06/25/2025 12:12:35

OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and ...

entera-bio-q1-eps-006-beats-007-estimate-sales-4200k
Entera Bio Q1 EPS $(0.06) Beats $(0.07) Es...
05/09/2025 20:09:52

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by...

entera-bio-announces-eb613-impact-on-both-trabecular-and-cortical-bone-compartments-with-6-months-of-treatment-in-post-menopausal-women-with-osteoporosis
Entera Bio Announces EB613 Impact On Both ...
04/15/2025 12:37:43

entera-bio-fy-2024-gaap-eps-025-sales-181000k-beat-139000k-estimate
Entera Bio FY 2024 GAAP EPS $(0.25), Sales...
03/28/2025 20:09:56

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.25) per share. The company reported quarterly sales of $181.000 thou...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
03/18/2025 15:47:53

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

Core News & Articles
OPKO Health And Entera Bio Enter Collabora...
03/17/2025 12:02:13

entera-bios-eb613-abstracts-for-osteoporosis-treatment-accepted-for-wco-iof-esceo-congress-from-april-10-13-2025-phase-2-shows-rapid-bmd-increase-enhanced-bone-formation-resorption-suppression
Entera Bio's EB613 Abstracts For Osteoporo...
02/19/2025 13:04:00

Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and prot...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
11/11/2024 11:57:52

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

entera-bio-q3-2024-gaap-eps-008-misses-006-estimate-sales-4200k-beat-4000k-estimate
Entera Bio Q3 2024 GAAP EPS $(0.08) Misses...
11/08/2024 21:10:45

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) ...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
10/07/2024 10:31:00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

hc-wainwright--co-reiterates-buy-on-entera-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Ente...
09/27/2024 10:34:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entera Bio (NASDAQ:ENTX) with a Buy and maintains $10 price ta...

entera-bio-shares-are-trading-higher-after-the-company-announced-results-showing-significant-systemic-exposure-and-a-favorable-pk-profile-in-its-obesity-and-metabolic-disorder-studies
Entera Bio shares are trading higher after...
09/25/2024 13:31:52

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION